Clinical Trial Update: Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients [Phase 2]

View source ↗

Summary

This document reports on a Phase 2 clinical trial evaluating the combination of bevacizumab and sorafenib as third-line therapy for metastatic renal cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN